A Phase 1a/b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-58067, an MTA-Cooperative PRMT5 Inhibitor in Patients With Advanced Solid Tumors

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515307-19-00

Enrollment

Registered

2025-01-29

Start date

2025-03-24

Completion date

Unknown

Last updated

2025-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced, or metastatic solid tumors with methylthioadenosine phosphorylase (MTAP) homozygous deletion and/or lost MTAP protein expression

None listed

Sex/Gender

All

Age

18 Years to No maximum

Denmark, France, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026